drugset / Trial / NCT00406588
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-04
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pardoprunox | Small molecule | 12 mg | — |
| Subject | Pardoprunox | Small molecule | 42 mg | — |
| Background | Levodopa | Small molecule | — | — |